thalidomide and hydroxyurea
Phase 2Small molecule
thalidomide and hydroxyurea is one of 58 small molecule programs targeting Beta-Thalassemia. It is currently in Phase 2.
2
Indications
2
Total Trials
1
Active Trials
57
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
84 competitors in Thalassemia
#DrugCompanyPhaseTrials
1Legalon
BBukwang Pharmaceutical
Phase 3
Winrevair
Merck & Co.Phase 2
Neoral
NovartisPhase 2
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 2
Jakafi
IncytePhase 2
Droxia
TTheravia
Phase 2
Dacogen
Sun PharmaPhase 2
Endari
EEmmaus Medical, Inc.
Phase 2
CTX001
Vertex PharmaceuticalsPhase 3
Campath
GGenzyme, a Sanofi Company
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Beta-Thalassemia1 trial
Long Term Beta Thalassemia Treatment: Findings From The Extension Period
Active, not recruiting·NNational Institute of Blood and Marrow Transplant (NIBMT), Pakistan·Phase 2·NCT06490601·30 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for thalidomide and hydroxyurea. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details